The most common problems associated with treating dyslipidemia are identifying patients who need to be treated, determining how aggressively they should be treated, and then encouraging them to comply with prescribed therapy. In addition, the degree of cardioprotection afforded by current agents is often suboptimal. Decision Resources Group’s Unmet Needs in Dyslipidemia analysis provides quantitative insight into U.S. and European physician perceptions of the unmet needs associated with dyslipidemia treatment, the goals of treatment, and the key drivers of therapy uptake. We discuss the commercial opportunities and how emerging therapies can capitalize on these opportunities.


Related Reports

Dyslipidemia - Landscape & Forecast - Disease Landscape & Forecast

Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD). Current lipid-modifying therapies, including statins, ezetimibe, bempedoic...

View Details

Dyslipidemia - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each co...

View Details

Dyslipidemia - Current Treatment - Detailed, Expanded Analysis: Physician Insights (US) : Hypertriglyceridemia

Hypertriglyceridemia refers to abnormalities in the concentration of triglycerides in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease and, with very high levels,...

View Details